Lipid effects of endocrine medications

Current Atherosclerosis Reports

Volumn 13, Issue 1, 2011, Pages 88-94

  Mihailescu, Dan V ^a   Vora, Avni ^a   Mazzone, Theodore ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cardiovascular; Cholesterol; Estrogen; Growth hormone; HDL; Insulin; LDL; Lipids; Testosterone; Thyroid hormone

Indexed keywords

CHOLESTEROL; CORTICOSTEROID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EPROTIROME; ESTROGEN; EXENDIN 4; GESTAGEN; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOCORTICOID; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEVOTHYROXINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; PREDNISOLONE; ROSIGLITAZONE; SITAGLIPTIN; TESTOSTERONE UNDECANOATE; VILDAGLIPTIN;

ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CUSHING DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; GLYCEMIC CONTROL; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOGONADISM; HYPOTHYROIDISM; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LOW DRUG DOSE; NONHUMAN; RISK BENEFIT ANALYSIS;

CHOLESTEROL, LDL; DYSLIPIDEMIAS; ENDOCRINE SYSTEM DISEASES; HORMONE ANTAGONISTS; HORMONES; HUMANS; LIPID METABOLISM;

EID: 79551561836     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0146-z     Document Type: Article

References (57)

1. RV Farese Jr TJ Yost RH Eckel, et al. 1991 Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans Metabolism 40 214 216 1:CAS:528:DyaK3MXjs1egtQ%3D%3D 10.1016/0026-0495(91)90178- Y 1988780
2. WT Garvey S Kwon D Zheng, et al. 2003 Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance Diabetes 52 453 462 1:CAS:528:DC%2BD3sXhtFansLw%3D 10.2337/diabetes.52.2.453 12540621 (Pubitemid 36173203)
3. KR Feingold C Grunfeld M Pang, et al. 1992 LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes Arterioscler Thromb Vasc Biol 12 1496 1502 1:STN:280:DyaK3s%2FotFCqtA%3D%3D
4. T Mazzone D Foster A Chait 1984 In vivo stimulation of low-density lipoprotein degradation by insulin Diabetes 33 333 338 1:CAS:528: DyaL2cXhs1yktbo%3D 10.2337/diabetes.33.4.333 6323237
5. RL Mason HM Hunt LM Hurxthal 1930 Blood cholesterol values in hyperthyroidism and hypothyroidism: their significance N Engl J Med 203 1273 1278 1:CAS:528:DyaA3MXhvFGgtg%3D%3D 10.1056/NEJM193012252032601
6. GR Thompson AK Soutar FA Spengel, et al. 1981 Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo Proc Natl Acad Sci U S A 78 2591 2595 1:CAS:528:DyaL3MXitVKltL0%3D 10.1073/pnas.78.4.2591 6264482 (Pubitemid 11067253)
7. O Pykalisto AP Goldberg JD Brunzell 1976 Reversal of decreased human adipose tissue lipoprotein lipase and hypertriglyceridemia after treatment of hypothyroidism J Clin Endocrinol Metab 43 591 600 1:CAS:528:DyaE28Xlslaitbg%3D 10.1210/jcem-43-3-591 956344
8. T O'Brien SF Dinneen PC O'Brien, et al. 1993 Hyperlipidemia in patients with primary and secondary hypothyroidism Mayo Clin Proc 68 860 866 8371604
9. M Ito T Arishima T Kudo, et al. 2007 Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients J Clin Endocrinol Metab 92 608 611 1:CAS:528:DC%2BD2sXitVaktrw%3D 10.1210/jc.2006-1605 17148561
10. PM Yen 2001 Physiological and molecular basis of thyroid hormone action Physiol Rev 81 1097 1142 1:CAS:528:DC%2BD3MXlt1Ohsrw%3D 11427693
11. L Johansson M Rudling TS Scanlan, et al. 2005 Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice Proc Natl Acad Sci U S A 102 10297 10302 1:CAS:528:DC%2BD2MXmvVeks7w%3D 10.1073/pnas.0504379102 16006512 (Pubitemid 41024974)
12. P Ladenson P Kristensen EC Ridgway, et al. 2010 Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia N Engl J Med 362 906 916 1:CAS:528:DC%2BC3cXjt1ylsL8%3D 10.1056/NEJMoa0905633 20220185 Eprotirome, a thyroid hormone analogue, has been shown in this randomized, prospective, placebo-controlled study to significantly decrease the levels of atherogenic lipoproteins in patients already receiving statin therapy
13. GM Darling JA Johns PI McCloud, et al. 1997 Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women N Engl J Med 337 595 601 1:CAS:528:DyaK2sXmtVGntb4%3D 10.1056/NEJM199708283370903 9271481 (Pubitemid 27360759)
14. S Hulley D Grady T Bush, et al. 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 605 613 1:CAS:528:DyaK1cXlslGqsLY%3D 10.1001/jama.280.7.605 9718051 (Pubitemid 28502636)
15. JE Rossouw GL Anderson RL Prentice, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333 1:CAS:528:DC%2BD38Xltlegs7k%3D 10.1001/jama.288.3.321 12117397
16. CJ Kim HC Jang DH Cho, et al. 1994 Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women Arterioscler Thromb 14 275 281 1:STN:280:DyaK2c7jslOjsw%3D%3D 8305420
17. UB Ottosson BG Johansson B von Schoultz 1985 Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone Am J Obstet Gynecol 151 746 750 1:STN:280:DyaL2M7ks1Srsw%3D%3D 3976784
18. SC Clarke J Kelleher H Lloyd-Jones, et al. 2002 A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study BJOG 109 1056 1062 1:CAS:528: DC%2BD38Xms1Grtro%3D 10.1111/j.1471-0528.2002.01544.x 12269682 (Pubitemid 35279139)
19. Haring R, Baumeister S, Volzke H, et al.: Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehab 2010 (in press).
20. SM Haffner L Mykkanen RA Valdez, et al. 1993 Relationship of sex hormones to lipids and lipoproteins in nondiabetic men J Clin Endocrinol Metab 77 1610 1615 1:CAS:528:DyaK2cXks1WrsQ%3D%3D 10.1210/jc.77.6.1610 8263149 (Pubitemid 24000922)
21. JI Makinen A Perheentupa K Irjala, et al. 2008 Endogenous testosterone and serum lipids in middle-aged men Atherosclerosis 197 688 693 1:CAS:528:DC%2BD1cXktFCksbY%3D 10.1016/j.atherosclerosis.2007.05.009 17588587 (Pubitemid 351417865)
22. M Zitzmann E Nieschlag 2007 Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men J Clin Endocrinol Metab 92 3844 3853 1:CAS:528:DC%2BD2sXht1SmtbnJ 10.1210/jc.2007-0620 17635942 (Pubitemid 47607632)
23. S Zgliczynski M Ossowski J Slowinska-Srzednicka, et al. 1996 Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men Atherosclerosis 121 35 43 1:CAS:528:DyaK28XhtlWhsb4%3D 10.1016/0021-9150(95)05673-4 8678922
24. PD Thompson EM Cullinane SP Sady, et al. 1989 Contrasting effects of testosterone and stanozolol on serum lipoprotein levels JAMA 261 1165 1168 1:CAS:528:DyaL1MXhvVKitbs%3D 10.1001/jama.261.8.1165 2915439 (Pubitemid 19062451)
25. S Basaria A Coviello T Travison, et al. 2010 Adverse Events Associated with Testosterone Administration N Engl J Med 363 109 122 1:CAS:528: DC%2BC3cXptFWmtrk%3D 10.1056/NEJMoa1000485 20592293 Testosterone administration in older men with limited mobility has been associated with an increased risk of cardiovascular adverse events
26. NM Fernandez-Balsells MH Murad M Lane, et al. 2010 Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis J Clin Endocrinol Metab 95 2560 2575 1:CAS:528:DC%2BC3cXnvValu7Y%3D 10.1210/jc.2009-2575 20525906 This meta-analysis included 51 studies and concluded that the adverse effects of testosterone therapy include a decrease in HDL cholesterol with no significant effect on cardiovascular outcomes or mortality
27. H De Boer GJ Blok HJ Voerman, et al. 1994 Serum lipid levels in growth hormone-deficient men Metabolism 43 199 203 10.1016/0026-0495(94)90245-3 8121302 (Pubitemid 24061853)
28. JA Barreto-Filho MR Alcantara R Salvatori, et al. 2002 Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia J Clin Endocrinol Metab 87 2018 2023 1:CAS:528:DC%2BD38XjsFGht7o%3D 10.1210/jc.87.5.2018 11994335 (Pubitemid 34521484)
29. JU Weaver JP Monson K Noonan, et al. 1995 The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults J Clin Endocrinol Metab 80 153 159 1:CAS:528:DyaK2MXjt1Okur4%3D 10.1210/jc.80.1.153 7829604
30. C Beauregard AL Utz AE Schaub, et al. 2008 Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study J Clin Endocrinol Metab 93 2063 2071 1:CAS:528:DC%2BD1cXntFamsb0%3D 10.1210/jc.2007-2371 18381581 (Pubitemid 351831516)
31. K Miller T Wexler P Fazeli, et al. 2010 Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement J Clin Endocrinol Metab 95 567 577 1:CAS:528: DC%2BC3cXitVaisr0%3D 10.1210/jc.2009-1611 20061426 Growth hormone replacement therapy in deficient patients post-treatment for acromegaly has been associated with an increased fat-free mass, and decreased visceral adipose tissue and hsCRP, but no effects on other cardiovascular markers
32. F Borson-Chazot A Serusclat Y Kalfallah, et al. 1999 Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency J Clin Endocrinol Metab 84 1329 1333 1:CAS:528: DyaK1MXisVyrt7w%3D 10.1210/jc.84.4.1329 10199774
33. A Colao C Di Somma S Spiezia, et al. 2008 Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency J Clin Endocrinol Metab 93 3416 3424 1:CAS:528:DC%2BD1cXhtFChurjL 10.1210/jc.2007-2810 18593773
34. P Ebden P McNally A Samanta, et al. 1989 The effects of high dose inhaled beclomethasone dipropionate on glucose and lipid profiles in normal and diet controlled diabetic subjects Respir Med 83 289 291 1:STN:280: DyaK3c7hs1KktQ%3D%3D 10.1016/S0954-6111(89)80198-2 2692092
35. WH Ettinger HF Klineffelter PO Kwiterowich 1987 Effect of short-term, low dose glucocorticoids on plasma lipoprotein lipids Atherosclerosis 63 167 172 1:CAS:528:DyaL2sXhtlWqsLs%3D 10.1016/0021-9150(87)90117-1 3493784
36. HK Choi JD Seeger 2005 Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey Arthritis Rheum 53 528 535 1:CAS:528:DC%2BD2MXpvVSlsbY%3D 10.1002/art.21329 16082633 (Pubitemid 41278917)
37. PC Souverein A Berard TP Van Staa, et al. 2004 Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study Heart 90 859 865 1:CAS:528: DC%2BD2cXnt1KmtL4%3D 10.1136/hrt.2003.020180 15253953 (Pubitemid 39005927)
38. MB Toft-Nielsen S Madsbad JJ Holst 2001 Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes J Clin Endocrinol Metab 86 3853 3860 1:CAS:528:DC%2BD3MXlvFeku70%3D 10.1210/jc.86.8.3853 11502823 (Pubitemid 32755988)
39. N Soltani M Kumar Y Glinka, et al. 2007 In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes Gene Ther 14 981 988 1:CAS:528: DC%2BD2sXmtVyjt74%3D 10.1038/sj.gt.3302944 17410180 (Pubitemid 46865509)
40. NT Lam TJ Kieffer 2002 The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent Minerva Endocrinol 27 79 93 1:STN:280:DC%2BD383isFajug%3D%3D 11961501
41. L Blonde J Klein J Han, et al. 2006 Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes Diabetes Obes Metab 8 436 447 1:CAS:528:DC%2BD28XnsFWhsLc%3D 10.1111/j.1463-1326.2006.00602.x 16776751 (Pubitemid 44349236)
42. DC Klonoff JB Buse LL Nielsen, et al. 2008 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 24 275 286 1:CAS:528:DC%2BD1cXhvVOgtLs%3D 18053320 This placebo-controlled trial demonstrated that extended use of exanetide could improve total cholesterol, triglyceride, HDL, and LDL levels
43. EA Schwartz J Koska MP Mullin, et al. 2010 Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type2 diabetes mellitus Atherosclerosis 212 217 222 1:CAS:528:DC%2BC3cXhtFams77M 10.1016/j.atherosclerosis.2010.05.028 20557887 This randomized, double-blinded, placebo-controlled crossover study showed that exenatide markedly reduced post-prandial concentrations of pro-atherogenic lipids, specifically triglycerides, apolipoproteins B-48 and CIII, and RLP
44. LE Eberly J Stamler JD Neaton 2003 Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease Arch Intern Med 163 1077 1083 10.1001/archinte.163.9.1077 12742806 (Pubitemid 36548936)
45. F Karpe G Steiner K Uffelman, et al. 1994 Postprandial lipoproteins and progression of coronary atherosclerosis Atherosclerosis 106 83 97 1:STN:280:DyaK2c3ovVygsw%3D%3D 10.1016/0021-9150(94)90085-X 8018110 (Pubitemid 24103802)
46. PG Scheffer T Teerlink JM Dekker, et al. 2008 Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn study Clin Chem 54 1325 1230 1:CAS:528:DC%2BD1cXpt12gtbY%3D 10.1373/clinchem.2008.103234 18556334
47. M Pirro P Mauriège A Tchernof, et al. 2002 Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study Atherosclerosis 160 377 384 1:CAS:528:DC%2BD38Xht1agu7g%3D 10.1016/S0021-9150(01)00588-3 11849661 (Pubitemid 34159331)
48. K Reynolds RB Goldberg 2006 Thiazolidinediones: beyond glycemic control Treat Endocrinol 5 25 36 10.2165/00024677-200605010-00004 16396516
49. DJ Betteridge 2007 Effects of pioglitazone on lipid and lipoprotein metabolism Diabetes Obes Metab 9 640 647 1:CAS:528:DC%2BD2sXhtFGgt7rO 10.1111/j.1463-1326.2007.00715.x 17697057 (Pubitemid 47261845)
50. JA Dormandy B Charbonnel DJ Eckland, et al. 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 1279 1289 1:CAS:528:DC%2BD2MXhtVOlu7fO 10.1016/S0140-6736(05)67528-9 16214598 (Pubitemid 41416583)
51. T Mazzone P Meyer S Feinstein, et al. 2006 Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2572 2581 1:CAS:528:DC%2BD28Xht12lsbbM 10.1001/jama.296.21.joc60158 17101640 (Pubitemid 44903861)
52. M Davidson PM Meyer S Haffner, et al. 2008 Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus Circulation 117 2123 2130 1:CAS:528:DC%2BD1cXks1Gjsb4%3D 10.1161/CIRCULATIONAHA. 107.746610 18413496 (Pubitemid 351572171)
53. RB Goldberg DM Kendall MA Deeg, et al. 2005 A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 1547 1554 1:CAS:528: DC%2BD2MXms12ntLk%3D 10.2337/diacare.28.7.1547 15983299 (Pubitemid 40923063)
54. B Charbonnel A Karasik J Liu, et al. 2006 : Efficacy and safety of the dipeptidylpeptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 29 2638 2643 1:CAS:528:DC%2BD2sXhtVGhtQ%3D%3D 10.2337/dc06-0706 17130197 (Pubitemid 44912191)
55. N Matikainen S Mänttäri A Schweizer, et al. 2006 Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 2049 2057 1:CAS:528: DC%2BD28XnslSitbo%3D 10.1007/s00125-006-0340-2 16816950 (Pubitemid 44168471)
56. MG Wulffelé A Kooy D de Zeeuw, et al. 2004 The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review J Intern Med 256 1 14 10.1111/j.1365-2796.2004. 01328.x 15189360 (Pubitemid 38813614)
57. RR Holman SK Paul MA Bethel, et al. 2008 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577 1589 1:CAS:528:DC%2BD1cXht1Wgt7nK 10.1056/NEJMoa0806470 18784090